SEC Comment Letter 0000000000-23-012422 to Syndax Pharmaceuticals Inc (SNDX) (CIK 0001395937) (SNDX)
Syndax Pharmaceuticals Inc (SNDX) (CIK 0001395937)
Date: Nov. 13, 2023 · CIK: 0001395937 · Accession: 0000000000-23-012422
AI Filing Summary & Sentiment
File numbers found in text: 001-37708
Letter
United States securities and exchange commission logo November 13, 2023 Keith Goldan Chief Financial Officer Syndax Pharmaceuticals Inc 35 Gatehouse Drive, Building D, Floor 3 Waltham, Massachusetts 02451 Re:Syndax Pharmaceuticals Inc Form 10K for Fiscal Year Ended December 31, 2022 File No. 001-37708 Dear Keith Goldan: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Form 10K for Fiscal Year Ended December 31, 2022 Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations Results of Operations Research and Development, page 62 1.We note in your discussion of research and development expenses you attribute a portion of the increased expenses to study activities related to your product candidates, axatilimab and revumenib. Please revise your future filings to address the following regarding your research and development expense:
•Revise to separately quantify the research and development costs tracked during each period presented for each of your key research and development projects. •For all other research and development expenses, provide other quantitative or qualitative disclosure that provides more transparency as to the type of research and development expenses incurred (i.e. quantify by nature or type of expense). •Separately quantify the amount of cost reimbursements that are recorded during the period as a reduction to research and development expense.
FirstName LastNameKeith Goldan Comapany NameSyndax Pharmaceuticals Inc November 13, 2023 Page 2 FirstName LastName Keith Goldan Syndax Pharmaceuticals Inc November 13, 2023 Page 2 •The total of costs broken out should reconcile to total research and development expense on the Statements of Operations. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Eric Atallah at 202-551-3663 or Daniel Gordon at 202-551-3486 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
November 13, 2023
Keith Goldan
Chief Financial Officer
Syndax Pharmaceuticals Inc
35 Gatehouse Drive, Building D, Floor 3
Waltham, Massachusetts 02451
Re:Syndax Pharmaceuticals Inc
Form 10K for Fiscal Year Ended December 31, 2022
File No. 001-37708
Dear Keith Goldan:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Form 10K for Fiscal Year Ended December 31, 2022
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations
Results of Operations
Research and Development, page 62
1.We note in your discussion of research and development expenses you attribute a portion
of the increased expenses to study activities related to your product candidates, axatilimab
and revumenib. Please revise your future filings to address the following regarding your
research and development expense:
•Revise to separately quantify the research and development costs tracked during each
period presented for each of your key research and development projects.
•For all other research and development expenses, provide other quantitative or
qualitative disclosure that provides more transparency as to the type of research and
development expenses incurred (i.e. quantify by nature or type of expense).
•Separately quantify the amount of cost reimbursements that are recorded during the
period as a reduction to research and development expense.
FirstName LastNameKeith Goldan
Comapany NameSyndax Pharmaceuticals Inc
November 13, 2023 Page 2
FirstName LastName
Keith Goldan
Syndax Pharmaceuticals Inc
November 13, 2023
Page 2
•The total of costs broken out should reconcile to total research and development
expense on the Statements of Operations.
In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Eric Atallah at 202-551-3663 or Daniel Gordon at 202-551-3486 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences